Stocks / NASDAQ / Metsera Inc.

Metsera Inc.

Industry: Health Care – Biotechnology: Pharmaceutical Preparations

Stock Symbol: MTSR – NASDAQ

Animal Usage: Animal Testing

Our Opinion

Metsera, Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.

Supporting Evidence:

The company confirms in corporate disclosures that it utilizes animal subjects for product testing.

“According to Meanwell, animal studies have suggested some of Metsera’s medicines may have superior characteristics — such as longer-lasting effects — than existing drugs.” Read the article for more details

Company Description

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, New York. As of November 13, 2025, Metsera, Inc. operates as a subsidiary of Pfizer Inc.

Company Website: https://www.metsera.com

Contact: info@metsera.com